In China,hepatitis B virus( HBV) infection remains a great threat to public health. Preventing the mother- to- child transmission( MTCT) of HBV is the main method to reduce the harm and disease burden caused by viral hepatitis in China. Recent studies have demonstrated that antiviral therapy with tenofovir disoproxil fumarate( TDF) during late pregnancy for mothers can further reduce MTCT of HBV. Meanwhile,Chinese Foundation for Hepatitis Prevention and Control launched the Hepatitis B Shield Project on July 25,2015. This project aims to further reduce or even eliminate MTCT of HBV by means of standard management of pregnant women with HBV via a mobile- health application. At present,China has made great achievements in fighting against HBV. We believe that the remarkable findings of such studies and the launch of the Chinese Shield Project will make the Chinese dream- HBV- free generation come true in the near future.
[1]WANG FS,FAN JG,ZHANG Z,et al.The global burden of liver disease:the major impact of China[J].Hepatology,2014,60(6):2099-2108.
|
[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
[3]World Health Organization.Tenofovir reduces mother-to-child transmission of hepatitis B:new study[EB/OL].[2016-06-16].http://www.who.int/hepatitis/news-events/hbv-mtcttenofovir/en/
|
[4]VISVANATHAN K,DUSHEIKO G,GILES M,et al.Managing HBV in pregnancy.Prevention,prophylaxis,treatment and follow-up:position paper produced by Australian,UK and New Zealand key opinion leaders[J].Gut,2016,65(2):340-350.
|
[5]ZOU H,CHEN Y,DUAN Z,et al.Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBs Ag-positive mothers[J].J Viral Hepat,2012,19(2):e18-e25.
|
[6]PAN CQ,HAN GR,JIANG HX,et al.Telbivudine prevents vertical transmission from HBe Ag-positive women with chronic hepatitis B[J].Clin Gastroenterol Hepatol,2012,10(5):520-526.
|
[7]CHEN HL,LEE CN,CHANG CH,et al.Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus[J].Hepatology,2015,62(2):375-386.
|
[8]ZHANG H,PAN CQ,PANG Q,et al.Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J].Hepatology,2014,60(2):468-476.
|
[9] XU WM,CUI YT,WANG L,et al.Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection:a multicentre,randomized,double-blind,placebo-controlled study[J].J Viral Hepat,2009,16(2):94-103.
|
[10]GREENUP AJ,TAN PK,NGUYEN V,et al.Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus[J].J Hepatol,2014,61(3):502-507.
|
[11]HAN GR,CAO MK,ZHAO W,et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J].JHepatol,2011,55(6):1215-1221.
|
[12]PAN CQ,DUAN Z,DAI E,et al.Tenofovir to prevent hepatitis Btransmission in mothers with high viral load[J].N Engl J Med,2016,374(24):2324-2334.
|
[13]FAN R,YIN X,HOU J.Prevention of peripartum hepatitis B transmission[J].N Engl J Med,2016,375(15):1496-1498.
|
[14]World Health Organization.Combating hepatitis B and C to reach elimination by 2030[EB/OL].[2016-05].http://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_eng.pdf
|
[15]FAN R,YIN X,LIU Z,et al.A hepatitis B-free generation in China:from dream to reality[J].Lancet Infect Dis,2016,16(10):1103-1105.
|